Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

Company profile
Ticker
LCI
Exchange
Website
CEO
Timothy Crew
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NETHERLANDS SECURITIES INC
SEC CIK
Corporate docs
Subsidiaries
Lannett Holdings, Inc. • Cody Laboratories, Inc. • Silarx Pharmaceuticals, Inc. • Kremers Urban Pharmaceuticals, Inc. ...
IRS number
230787699
LCI stock data
Investment data
Securities sold
Number of investors
Calendar
10 May 22
18 Aug 22
30 Jun 23
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 21 | Jun 20 | Jun 19 | Jun 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 111.11M | 111.11M | 111.11M | 111.11M | 111.11M | 111.11M |
Cash burn (monthly) | (no burn) | (no burn) | 12.09M | 15.81M | 652.67K | (no burn) |
Cash used (since last report) | n/a | n/a | 55.79M | 73M | 3.01M | n/a |
Cash remaining | n/a | n/a | 55.31M | 38.11M | 108.1M | n/a |
Runway (months of cash) | n/a | n/a | 4.6 | 2.4 | 165.6 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jul 22 | Kozlowski John | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 8,114 | 4.71K | 138,954 |
31 Jul 22 | Abt John | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 3,924 | 2.28K | 119,775 |
31 Jul 22 | Cavanaugh Maureen | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 5,656 | 3.28K | 143,896 |
31 Jul 22 | Crew Timothy C | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 19,368 | 11.23K | 589,291 |
31 Jul 22 | Israel Samuel H | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 10,154 | 5.89K | 156,644 |
29 Jul 22 | Kozlowski John | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 3,330 | 1.93K | 147,068 |
29 Jul 22 | Abt John | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 1,798 | 1.04K | 123,699 |
29 Jul 22 | Cavanaugh Maureen | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 3,042 | 1.76K | 149,552 |
29 Jul 22 | Crew Timothy C | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 9,227 | 5.35K | 608,659 |
29 Jul 22 | Israel Samuel H | Common Stock | Payment of exercise | Dispose F | No | No | 0.58 | 5,465 | 3.17K | 166,798 |
Institutional ownership, Q2 2022
16.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 12 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 33.77M |
Total shares | 22.22M |
Total puts | 79.4K |
Total calls | 60.3K |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Telemus Capital | 7.38M | $4.28M |
Renaissance Technologies | 2.2M | $1.27M |
D. E. Shaw & Co | 1.89M | $12.3M |
D. E. Shaw & Co. | 1.77M | $1.03M |
MintBroker International | 1.4M | $7.21M |
LSV Asset Management | 1.06M | $615K |
Vanguard | 704.19K | $409K |
BLK Blackrock | 576.21K | $334K |
Two Sigma Advisers | 551.9K | $320K |
Staley Capital Advisers | 515.15K | $299K |
Financial report summary
?Competition
Impax Laboratories • Elite Pharmaceuticals • Mylan II B.V. • Amneal Pharmaceuticals • Mirum PharmaceuticalsRisks
- The generic pharmaceutical industry is highly competitive.
- We have and will continue to enter into strategic alliances and collaborations with third parties, including companies based outside of the U.S., for the commercialization of some of our drug candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these drug candidates.
- The development, approval process, manufacture and commercialization of biosimilar products involve unique challenges and uncertainties, and our failure to successfully introduce biosimilar products could have a negative impact on our business, financial condition, results of operations and cash flows.
- If we are unable to obtain sufficient supplies from key suppliers that in some cases may be the only source of finished products or raw materials, our ability to deliver our products to the market may be impeded.
- Our policies regarding returns, allowances and chargebacks and marketing programs adopted by wholesalers may reduce our revenues in future fiscal periods.
- Health care initiatives and other third-party payor cost-containment pressures have and could continue to cause us to sell our products at lower prices, resulting in decreased revenues.
- Sales of our products may continue to be adversely affected by the continuing consolidation of our distribution network and the concentration of our customer base.
- We expend a significant amount of resources on research and development efforts that may not lead to successful product introductions.
- Our substantial indebtedness may adversely affect our financial health.
- The agreements and instruments governing our debt, contain restrictions and limitations that could significantly impact our ability to operate our business.
- Due to many factors beyond our control, we may not be able to generate sufficient cash to service all of our indebtedness and meet our other ongoing liquidity needs and we may be forced to take other actions to satisfy our obligations under our debt agreements, which may not be successful.
- Our gross profit may fluctuate from period to period depending upon our product sales mix, our product pricing and our costs to manufacture or purchase products.
- A relatively small group of products may represent a significant portion of our revenues, gross profit, or net earnings from time to time.
- If our intangible assets become impaired, we may be required to record a significant charge to earnings.
- We may incur additional tax liabilities related to our operations.
- Our tax returns and positions are subject to review and audit by the Internal Revenue Service and other tax authorities, and any adverse outcomes resulting from any examination of our tax returns could adversely affect our liquidity and financial condition.
- Governmental investigations into sales and marketing practices in the generic pharmaceutical industry and claims by private parties relating to such investigations may result in substantial penalties or settlements.
- The recent enactment of State laws affecting the pricing of our products could have the effect of reducing our profitability.
- Extensive industry regulation has had and will continue to have, a significant impact on our business in the area of cost of goods, especially our product development, manufacturing and distribution capabilities.
- If brand pharmaceutical companies are successful in limiting the use of generics through their legislative and regulatory efforts, our sales of generic products may suffer.
- The generic pharmaceutical industry is characterized by intellectual property litigation and third parties may claim that we infringe on their proprietary rights, which could result in litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages or prevent us from marketing our existing or future products.
- Our reporting and payment obligations related to our participation in U.S. federal healthcare programs, including Medicare, Medicaid and the Department of Veterans Affairs, are complex and often involve subjective decisions that could change as a result of new business circumstances, new regulations or agency guidance, or advice of legal counsel. Any failure to comply with those obligations could subject us to investigation, penalties, and sanctions.
- We may need to change our business practices to comply with changes to fraud and abuse laws.
- We may become subject to federal and state false claims litigation brought by private individuals and the government.
- Federal regulation of arrangements between manufacturers of brand and generic products could adversely affect our business.
- Investigations of the calculation of average wholesale prices may adversely affect our business.
- We may incur product liability losses or recall expenses relating to the sale of products containing nitrosamines.
- Increasing scrutiny and evolving expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.
- Public health threats, including a pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business and financial results.
- The loss of key personnel could cause our business to suffer.
- We are increasingly dependent on information technology and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
- Rising insurance costs, as well as the inability to obtain certain insurance coverage for risks faced by us, could negatively impact profitability.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
absolute, analyst, CDMO, Chartwell, deficiency, delist, delisting, demonstrate, denial, drawn, failure, Gastrointestinal, ineffective, lengthy, Manual, meaningful, meet, noncash, NY, NYSE, oversight, prevailing, regain, reputation, resilience, retain, retained, Societal, successful, suspension
Removed:
adhere, attention, center, cleaning, conform, country, discontinued, distancing, enabling, enhanced, experiencing, fewer, full, home, instituted, intact, intermittent, job, Migraine, Numbrino, ongoing, overtime, perform, reclassified, remote, remotely, repayment, sanitizing, shut, social, stocking, Sumatriptan, superseded, supporting, title, unfavorably, vendor, work
Financial reports
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 May 22
8-K
Lannett Reports Fiscal 2022 Third-quarter Financial Results
5 May 22
8-K
LANNETT announces receipt of notice of non-compliance from nyse related to stock price
18 Mar 22
8-K
LANNETT announces receipt of notice of non-compliance from nyse
4 Mar 22
8-K
LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million
4 Mar 22
8-K
Results of Operations and Financial Condition
4 Feb 22
8-K
Submission of Matters to a Vote of Security Holders
27 Jan 22
8-K
Departure of Directors or Certain Officers
20 Jan 22
8-K
Results of Operations and Financial Condition
4 Nov 21
8-K
Full-year Financial Results
26 Aug 21
Registration and prospectus
S-8
Registration of securities for employees
4 Feb 22
424B3
Prospectus supplement
27 May 21
D
Indefinite amount in equity / options / securities to be acquired, sold $27.96M, 22 investors
7 May 21
S-8
Registration of securities for employees
22 Feb 21
S-3
Shelf registration
20 Dec 19
S-8
Registration of securities for employees
22 Mar 19
S-3ASR
Automatic shelf registration
12 Feb 18
S-3ASR
Automatic shelf registration
11 May 17
S-8
Registration of securities for employees
22 Jan 14
Other
EFFECT
Notice of effectiveness
28 May 21
CORRESP
Correspondence with SEC
24 May 21
UPLOAD
Letter from SEC
12 May 21
EFFECT
Notice of effectiveness
27 Jan 20
CORRESP
Correspondence with SEC
20 Jan 20
CORRESP
Correspondence with SEC
8 Jan 20
UPLOAD
Letter from SEC
30 Dec 19
CT ORDER
Confidential treatment order
27 Feb 19
UPLOAD
Letter from SEC
25 Apr 17
CORRESP
Correspondence with SEC
28 Mar 17
Ownership
4
LANNETT / John Abt ownership change
1 Aug 22
4
LANNETT / Maureen Cavanaugh ownership change
1 Aug 22
4
LANNETT / Timothy C Crew ownership change
1 Aug 22
4
LANNETT / Samuel H Israel ownership change
1 Aug 22
4
LANNETT / JOHN KOZLOWSKI ownership change
1 Aug 22
4
LANNETT / JOHN KOZLOWSKI ownership change
28 Jul 22
4
LANNETT / Samuel H Israel ownership change
28 Jul 22
4
LANNETT / Maureen Cavanaugh ownership change
28 Jul 22
4
LANNETT / Timothy C Crew ownership change
28 Jul 22
4
LANNETT / John Abt ownership change
28 Jul 22
Transcripts
2022 Q3
Earnings call transcript
5 May 22
2022 Q2
Earnings call transcript
4 Feb 22
2022 Q1
Earnings call transcript
4 Nov 21
2021 Q4
Earnings call transcript
26 Aug 21
2021 Q3
Earnings call transcript
6 May 21
2021 Q2
Earnings call transcript
4 Feb 21
2021 Q1
Earnings call transcript
4 Nov 20
2020 Q4
Earnings call transcript
26 Aug 20
2020 Q3
Earnings call transcript
6 May 20
2020 Q2
Earnings call transcript
5 Feb 20
Reddit threads
I love you Ariel Zilber
5 Aug 22
What stocks do you think are the most overvalued right now?
14 Jun 22
37 stocks with (A) over 3% yield, (B) over 10% 3-year dividend growth and (C) consecutive 5 Years of Dividend Growth. List in the comments.
27 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Upcoming US dividend March 9
9 Mar 22
What are you doing to invest in the EV market?
11 Feb 22
Daily Discussion Thread - February 3rd, 2022
3 Feb 22
Daily Discussion Thread - February 2nd, 2022
2 Feb 22